Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% above its 5-year average of -3.86%, near the high end of its 5-year range (-943.37%–97.20%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
-53.25%
GROSS MARGIN AVG 5Y
-3.86%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
SAB Biotherapeutics, Inc.
Market Cap
$270.41M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-53.25%
5Y Avg
-3.86%
Market Cap
$270.61M
Gross Margin
92.82%
TTM Avg
94.13%
3Y Avg
92.76%
5Y Avg
92.02%
Market Cap
$270.20M
Gross Margin
79.45%
TTM Avg
80.09%
3Y Avg
80.50%
5Y Avg
80.39%
Market Cap
$270.00M
Gross Margin
85.79%
TTM Avg
85.31%
3Y Avg
84.59%
5Y Avg
70.69%
Market Cap
$271.00M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$271.28M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$264.75M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1258.31%
5Y Avg
-887.92%
Market Cap
$265.36M
Gross Margin
93.41%
TTM Avg
92.41%
3Y Avg
88.66%
5Y Avg
85.93%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $270.41M | 0.00% | 0.00% | -53.25% | -3.86% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.61M | 92.82% | 94.13% | 92.76% | 92.02% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.20M | 79.45% | 80.09% | 80.50% | 80.39% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $270.00M | 85.79% | 85.31% | 84.59% | 70.69% |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | -94.12% | -431.85% | -231.35% | -189.25% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.28M | 0.00% | 0.00% | 0.00% | 0.00% |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.43M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.75M | 0.00% | 0.00% | -1258.31% | -887.92% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.36M | 93.41% | 92.41% | 88.66% | 85.93% |
| Palisade Bio, Inc. (PALI)vs › | $262.75M | 0.00% | 0.00% | 25.00% | 16.67% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -585.03% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | -288.39% |
| 2024-03-31 | -110.12% |
| 2023-12-31 | -209.50% |
| 2023-09-30 | 22.25% |
| 2023-06-30 | -943.37% |
| 2023-03-31 | -58.87% |
| 2022-12-31 | 57.26% |
| 2022-09-30 | 74.65% |
| 2022-06-30 | -35.18% |
| 2022-03-31 | -12.89% |
| 2021-12-31 | 3.71% |
| 2021-09-30 | 97.20% |
| 2021-06-30 | -2.60% |
| 2021-03-31 | 24.49% |
| 2020-12-31 | -8.36% |
